CytoImmune Therapeutics, LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CytoImmune Therapeutics, LLC
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
- Gene Therapy, Cell Therapy